Hongming Chen
陈红敏
Hongming Chen is a U.S. National Academy of Engineering academician and co-founder of METiS Pharmaceuticals (剂泰医药), an AI-driven drug-delivery company that listed on the Hong Kong Stock Exchange in May 2026 . She helped launch the firm in 2020 alongside MIT-trained scientists Caida Lai and Wenshou Wang, having begun preparatory work as early as 2017 . At METiS she serves as co-founder and Chief R&D Officer, leading a team that merges medicinal chemistry expertise with an AI platform . The company, in which she is described as Lai's partner, has raised multiple nine-figure funding rounds from investors including Source Code Capital and 5Y Capital .
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Heart Capital Congratulates METiS Pharmaceuticals on Successful Listing on the Main Board of the Hong Kong Stock Exchange | Heart Star PORTFOLIO
The world's first publicly listed AI drug delivery company.
The SpaceX of Pharma: Caida Lai's Nanorocket
Only those with fire in their eyes can build rockets.
MaKe | MaHui Member METiS Pharmaceuticals Closes $100 Million Series C, Leading the "AI + Drug Delivery" Track
5Y News | 5Y Capital Portfolio Company METiS Pharmaceuticals Closes $100 Million Series C Round
Focused on "AI-powered drug delivery."
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
Code Engraved | METiS Pharmaceuticals Announces Two Consecutive Rounds totaling $150 Million
The most advanced pipeline programs are expected to begin pivotal clinical trials in 2023.
Source Code Capital portfolio company METiS Pharmaceuticals announced the completion of angel+ and Pre-A funding rounds totaling over 100 million yuan, with existing investor Source Code Capital continuing to increase its stake.
It was the first to propose building an AI-driven formulation development platform, jointly advancing new formulation drugs to clinical trials.
AI-powered pharmaceutical formulation development company "METiS" announced the completion of a multi-million dollar angel round — Source Code Capital participated as a follow-on investor.
The world's first startup to use AI to drive pharmaceutical formulation development, dedicated to providing drug companies with rapid, precise intelligent formulation R&D through high-throughput formulation platforms and AI computing technologies.
